Last reviewed · How we verify
An Open-label, Multiple-dose, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of amlodipine10mg and candesartan32mg in Healthy Male Volunteers
Clinical trial to evalate the pharmacokinetic interactions and safety between single dose of amlodipine10mg and candesartan32mg and combiation dose amlodipine10mg with candesartan32mg in healthy male volunteers.
Details
| Lead sponsor | HanAll BioPharma Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 36 |
| Start date | 2012-12 |
| Completion | 2013-08 |
Conditions
- Hypertension
Interventions
- Candesartan32mg
- Amlodipine10mg
Primary outcomes
- Part A : AUC, Cmax of Candesartan — Over a 24-hour sampling period
- Par B : AUC, Cmax of Amlodipine — Over a 24-hour sampling period
Countries
South Korea